COVID-19 and Scarce Hospital Resources:B·R·A·H·M·S MR-proADM KRYPTOR for Risk Stratification to Support Decisions on the Required Level of Care Learn more
MR-proADM: A Biomarker of Microcirculatory and Endothelial Damage
Mid-regional proadrenomedullin (MR-proADM) is a blood biomarker that is elevated in diseased states in response to the increased hyper-permeability of the microcirculation, and subsequent plasma leakage into the extracellular space. In addition, adrenomedullin has potent vasodilatory properties.
It can be used in both the emergency and intensive care departments to assess the severity of an infection on the host response and the risk of disease progression.
Use in the emergency department (ED)
- Decrease time to treatment
- Increase out-patient number
- Reduce length of stay
Video: B·R·A·H·M·S MR-proADM KRYPTOR in the emergency department (ED)
Increase rate of outpatient treatment
Accurate rule-out of further disease progression with Thermo Scientific B·R·A·H·M·S MR-proADM KRYPTOR
Use in the intensive care unit (ICU)
- Maximize patient safety
- Guide the most appropriate treatment
- Provide an early warning of additional complications
Video: Use of B·R·A·H·M·S MR-proADM KRYPTOR in the general ICU of University Hospital Tor Vergata
Dr Francesca Leonardis, Director of the General ICU of Hospital Tor Vergata in Rome, explains how biomarker MR-proADM can be used to monitor patients with infection throughout their hospital stay to make decisions on disposition and level of care.